Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants
Gan and Lee Pharmaceuticals, USA · Obesity and Overweight
Phase 2
Completed
326
2026-07
Industry sponsor intelligence
Gan and Lee Pharmaceuticals, USAClinical Pipeline.
Lead-sponsor view of Gan and Lee Pharmaceuticals, USA's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 1
- Recruiting
- 0
- Active
- 0
- Completed
- 1
- Results posted
- 0
- Avg enrollment
- 326
Pipeline overview
Programs by phase and activity.
Velocity
Gan and Lee Pharmaceuticals, USA trials by start year
Study start year · indexed snapshot
Development
Trials by phase
1phase labels
Early Phase 10
Phase 10
Phase 21
Phase 30
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Glucagon → | 1 | 0 | 1 | 0 | 0 | 0 |
| Tirzepatide → | 1 | 0 | 1 | 0 | 0 | 0 |
Active peptide trials
In motion now.
No studies in this snapshot.
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
Search sponsor records
All Gan and Lee Pharmaceuticals, USA studies.
This page groups studies where Gan and Lee Pharmaceuticals, USA is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
1 matching study
Last registry update first
Recent updates